Biosimilar Litigation Trends: Settlements, Declaratory Judgment Rejections, Congressional Intervention
Executive Summary
Of the 27 suits brought so far, four have resulted in patent settlements; restarting patent dance is new trend for ongoing litigation.
You may also be interested in...
Keeping Track: Yupelri Is Latest Novel Drug Approved, But Bad News For Biosimilars
The latest drug development news and highlights from our US FDA Performance Tracker.
AbbVie Inks Sixth Humira Biosimilar Settlement, Battles Boehringer's 'Unclean Hands' Claim
Boehringer stands out in its decision to litigate rather than settle, and the firm has obtained AbbVie's settlement agreements with other biosimilar makers.
AbbVie Inks Sixth Humira Biosimilar Settlement, Battles Boehringer's 'Unclean Hands' Claim
Boehringer stands out in its decision to litigate rather than settle, and the firm has obtained AbbVie's settlement agreements with other biosimilar makers.